CORESTEMCHEMON Inc. 166480
KRX · South Korea · Health Technology
KRW 2,315.00+55.00 (+2.43%)
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · KRW · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
MakklerAI · PRO
MakklerPRO is required for MakklerAI questions and forward scenarios grounded in structured data for the selected stock.
Upgrade to MakklerPROUpgrade to MakklerPRO to see the Makkler Fair Value calculation, the fundamental score and the multiples behind it.
Upgrade to MakklerPROUpgrade to MakklerPRO to see a 1-5 score for profitability, growth, cash-flow quality, and balance-sheet health.
Upgrade to MakklerPROUpgrade to MakklerPRO to see an AI-generated executive summary and bull/bear breakdown built from this stock's financial data.
Upgrade to MakklerPRO| Company | Market cap | P/E | P/B | P/S | Net margin | Revenue growth | Dividend yield | Beta |
|---|---|---|---|---|---|---|---|---|
| 166480CORESTEMCHEMON Inc. | KRW 113.16B | — | 2.5 | 5.9 | -152.0% | -26.3% | 0.0% | 1.1 |
| 002620JEIL PHARMA HOLDINGS INC. | KRW 112.83B | 13.6 | 0.4 | 0.2 | 1.4% | -15.5% | 1.0% | 0.1 |
| 001540AHN-GOOK PHARMACEUTICAL Co., Ltd. | KRW 113.65B | 5.1 | 0.6 | 0.3 | 6.3% | 18.7% | 6.3% | 0.5 |
| 334970Prestige Biologics Co., Ltd. | KRW 110.95B | — | 1.2 | 4.2 | -192.1% | 112.8% | 0.0% | 0.1 |
| 106190High Tech Pharm. Co., Ltd. | KRW 106.33B | 9.1 | 0.8 | 1.5 | 17.2% | -7.0% | 1.5% | 0.1 |
| 131030OPTUS Pharmaceutical Co. Ltd. | KRW 105.26B | 7.4 | 0.6 | 1.2 | 14.6% | 14.1% | 0.0% | -0.0 |
| 175250Icure Pharmaceutical Incorporation | KRW 105.25B | — | 2.2 | 0.6 | -19.7% | 26.3% | 0.0% | 0.3 |
| 002210Dongsung Pharmaceutical Co., Ltd. | KRW 122.45B | — | 1.4 | 1.5 | -14.0% | -9.1% | 0.0% | -0.5 |
| 235980MedPacto, Inc. | KRW 104.20B | — | 2.6 | 20.9 | -283.1% | 293.4% | 0.0% | 0.2 |
| Peer median | 8.2 | 1.0 | 1.3 | -6.3% | 16.4% | 0.0% | 0.1 |
Peers are selected automatically from companies in the same industry. Extreme ratios (a loss-making company's P/E, or one distorted by a one-off item) are not adjusted away, which is why the summary row uses the median rather than the average. Not investment advice. The ratios in this table come from one outside provider for every company, so the comparison is internally consistent; they can differ from the filing-derived ratios higher up the page because the definitions differ.